Under construction – not a live service
Sign in
Taking people in SpainPhase 1

Tests NILK-2301 in adults with advanced colorectal cancer with low tumor volume

Tests the antibody NILK-2301 in adults aged 18 to 64 with advanced colorectal cancer.

Key facts

Who runs it
NovImmune S.A.
Where
Barcelona and Madrid, SpainSee the 3 sites
Registry title
A PHASE I STUDY OF THE CEACAM5 x CD3 ANTIBODY NILK-2301 IN COLORECTAL CANCER
Status
Recruiting
Phase
Phase 1
People taking part
12 people, planned
Started
5 Apr 2024
Expected to end
29 Apr 2027
Type of study
Interventional
Record updated
21 September 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with locally advanced or metastatic colorectal cancer with a low tumor volume.

Age
18 to 64 years
Sex
All sexes can join.
Disease stage
Locally advanced or metastatic colorectal cancer with low tumor volume.

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 64 years old?

Where in Spain

  • Vall D'hebron Institut De RecercaBarcelona, SpainTaking people
  • Hospital Universitario Fundación Jiménez DíazMadrid, SpainTaking people
  • Hospital Universitario HM SanchinarroMadrid, SpainTaking people

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).
Plain-language title
Tests NILK-2301 in adults with advanced colorectal cancer with low tumor volumeGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 9 November 2026.
Fit questions
Built from 2023-508058-24-01, who can take part
Record updated
21 September 2026